Oncolytics Biotech
ONCY
42 hedge funds and large institutions have $1.07M invested in Oncolytics Biotech in 2024 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
2% more funds holding
Funds holding: 41 → 42 (+1)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
0.12% less ownership
Funds ownership: 1.78% → 1.66% (-0.12%)
17% less capital invested
Capital invested by funds: $1.3M → $1.07M (-$224K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
+$25.5K |
| 2 |
NDSI
Newman Dignan & Sheerar Inc
Providence,
Rhode Island
|
+$21.6K |
| 3 |
RC
Rovin Capital
Mesa,
Arizona
|
+$20.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$17K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$13.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$110K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$56.8K |
| 3 |
VF
Virtu Financial
New York
|
-$27K |
| 4 |
Jane Street
New York
|
-$12.6K |
| 5 |
BCV
Banque Cantonale Vaudoise
Lausanne,
Switzerland
|
-$12K |
ONCY Hedge Fund Activity: Q3 2024 in Review
42 of the 6,979 institutional investors tracked by Wall St. Rank reported a position in Oncolytics Biotech (ONCY) for Q3 2024, worth a combined $1.07M — down 17% from $1.3M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ONCY positions and 6 closed out — a net gain of 1 holder — while 8 added to existing stakes and 8 trimmed.
The largest buyer was SeaCrest Wealth Management, opening a new position worth an estimated $25.5K. The largest seller was Morgan Stanley, cutting an estimated $110K.
- 42 institutional investors held Oncolytics Biotech (ONCY) as of Q3 2024, up from 41 in Q2 2024.
- Funds reported $1.07M of Oncolytics Biotech stock for Q3 2024, down 17% quarter-over-quarter.
- 7 funds opened new Oncolytics Biotech positions in Q3 2024 and 6 closed out, a net change of +1 holder.
- The largest Oncolytics Biotech buyer in Q3 2024 was SeaCrest Wealth Management, an estimated $25.5K added.
- The largest Oncolytics Biotech seller in Q3 2024 was Morgan Stanley, an estimated $110K sold.
Based on aggregated 13F filings for Q3 2024.